These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 15175271)
21. Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans. Senthilkumari S; Lalitha P; Prajna NV; Haripriya A; Nirmal J; Gupta P; Velpandian T Curr Eye Res; 2010 Nov; 35(11):953-60. PubMed ID: 20958183 [TBL] [Abstract][Full Text] [Related]
22. An alternative approach to determine oral bioavailability of drugs that follow Michaelis-Menten elimination: a case study with voriconazole. Verlindo de Araujo B; Farias da Silva C; Costa TD Pharmacology; 2010; 86(3):163-7. PubMed ID: 20714206 [TBL] [Abstract][Full Text] [Related]
23. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Burkhardt O; Thon S; Burhenne J; Welte T; Kielstein JT Int J Antimicrob Agents; 2010 Jul; 36(1):93-4. PubMed ID: 20381320 [No Abstract] [Full Text] [Related]
24. Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration. Malone ME; Corrigan OI; Kavanagh PV; Gowing C; Donnelly M; D'Arcy DM Int J Antimicrob Agents; 2013 Oct; 42(4):335-42. PubMed ID: 23920093 [TBL] [Abstract][Full Text] [Related]
25. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Mohammedi I; Piens MA; Padoin C; Robert D Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):358-60. PubMed ID: 15875225 [No Abstract] [Full Text] [Related]
26. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251 [TBL] [Abstract][Full Text] [Related]
27. Determination of the antifungal agent voriconazole in human plasma using a simple column-switching high-performance liquid chromatography and its application to a pharmacokinetic study. Nakagawa S; Suzuki R; Yamazaki R; Kusuhara Y; Mitsumoto S; Kobayashi H; Shimoeda S; Ohta S; Yamato S Chem Pharm Bull (Tokyo); 2008 Mar; 56(3):328-31. PubMed ID: 18310944 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic profile of voriconazole in a critically ill patient on therapeutic plasma exchange. Spriet I; Brüggemann RJ; Annaert P; Meersseman P; Van Wijngaerden E; Lagrou K; Willems L Ther Drug Monit; 2013 Feb; 35(1):141-3. PubMed ID: 23296095 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis. Luke DR; Wood ND; Tomaszewski KE; Damle B Nephrol Dial Transplant; 2012 Mar; 27(3):1207-12. PubMed ID: 21868395 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Malone RS; Fish DN; Abraham E; Teitelbaum I Antimicrob Agents Chemother; 2001 Nov; 45(11):3148-55. PubMed ID: 11600370 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Hafner V; Czock D; Burhenne J; Riedel KD; Bommer J; Mikus G; Machleidt C; Weinreich T; Haefeli WE Antimicrob Agents Chemother; 2010 Jun; 54(6):2596-602. PubMed ID: 20368400 [TBL] [Abstract][Full Text] [Related]
35. Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing. Passler NH; Chan HM; Stewart AJ; Duran SH; Welles EG; Lin HC; Ravis WR J Vet Pharmacol Ther; 2010 Feb; 33(1):35-41. PubMed ID: 20444023 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. Groll AH; Kolve H; Ehlert K; Paulussen M; Vormoor J J Antimicrob Chemother; 2004 Jan; 53(1):113-4. PubMed ID: 14657088 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis. Clifton IJ; Whitaker P; Metcalfe R; Phillip M; Shaw N; Conway SP; Peckham DG J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443 [No Abstract] [Full Text] [Related]
38. What is the "therapeutic range" for voriconazole? Lewis RE Clin Infect Dis; 2008 Jan; 46(2):212-4. PubMed ID: 18171252 [No Abstract] [Full Text] [Related]
39. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Muhl E; Martens T; Iven H; Rob P; Bruch HP Eur J Clin Pharmacol; 2000 Dec; 56(9-10):671-8. PubMed ID: 11214774 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Eiden C; Cociglio M; Hillaire-Buys D; Eymard-Duvernay S; Ceballos P; Fegueux N; Peyrière H Xenobiotica; 2010 Oct; 40(10):701-6. PubMed ID: 20642349 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]